Last update Aug. 20, 2022

塩酸レルカニジピン

Low Risk

Possibly safe. Probably compatible. Mild risk possible. Follow up recommended. Read the Comment.

It is a dihydropyridine-type calcium channel blocker. It is used in the treatment of hypertension. Oral administration once daily.

At latest update no published data were found on excretion into breast milk.

Its high plasma protein binding capacity makes it unlikely any passage to the breast milk, however, its high lipid solubility facilitates excretion into it.

Although it has a low oral bioavailability, it may increase to four times if administered with a fatty meal (ARTG 2014), which would increase the oral absorption in the infant.

Evidence on other antihypertensive drugs of the same family with similar structure, pharmacokinetics and action profile (nifedipine, nimodipine, nicardipine) has shown that they are excreted into milk in non-significant amount.

Until more extensive published data about this drug regarding breastfeeding are available a safer alternative drug should be used, especially during the neonatal period and/or in case of premature infants.

Alternatives

Suggestions made at e-lactancia are done by APILAM team of health professionals, and are based on updated scientific publications. It is not intended to replace the relationship you have with your doctor but to compound it. The pharmaceutical industry contraindicates breastfeeding, mistakenly and without scientific reasons, in most of the drug data sheets.

Jose Maria Paricio, Founder & President of APILAM/e-Lactancia

Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.

Thank you for helping to protect and promote breastfeeding.

José María Paricio, founder of e-lactancia.

Other names

塩酸レルカニジピン is Lercanidipine Hydrochloride in Japanese.

Is written in other languages:

塩酸レルカニジピン is also known as

Group

塩酸レルカニジピン belongs to this group or family:

Tradenames

Main tradenames from several countries containing 塩酸レルカニジピン in its composition:

Pharmacokinetics

Variable Value Unit
Oral Bioavail. 10 %
Molecular weight 648 daltons
Protein Binding 98 %
Tmax 1.5 - 3 hours
8 - 10 hours

References

  1. ARTG. Lercanidipine. Product Monograph. 2014 Full text (in our servers)
  2. AEMPS. Lercanidipino. Ficha técnica. 2011 Full text (in our servers)

Total visits

1,706

Help us improve this entry

How to cite this entry

Do you need more information or did not found what you were looking for?

   Write us at elactancia.org@gmail.com

e-lactancia is a resource recommended by Academy of Breastfeeding Medicine - 2006 of United States of America

Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM